桂附地黄丸联合盐酸坦洛新治疗良性前列腺增生症60例

目的:观察桂附地黄丸联合坦洛新对良性前列腺增生(BPH)(肾阳虚证)疾病进展的影响。方法:将116例BPH患者采用随机按数字表法分为西药组56例和观察组60例。西药组口服盐酸坦洛新缓释胶囊,0.2 mg/次,1次/晚;观察组在西药组治疗的基础上加用桂附地黄丸,6 g/次,2次/d,口服。两组疗程均为12周。进行国际前列腺症状评分(I-PSS),肾阳虚证、排尿症状对生活质量(QOL)评分;测量残余尿量(PVR),最大尿流率(Qmax)和平均尿流率(Qave);采用B超检测前列腺大小和质量;记录夜尿次数,以上指标治疗前后各评价1次。结果:观察组临床疗效总有效率为91.66%,西药组为76.78%,观察组优于西药组(P0.05);治疗后观察组I-PSS,肾阳虚证和QOL评分均比西药组低(P0.01);治疗后观察组PVR少于西药组(P0.01),观察组Qmax和Qave高于西药组(P0.01);治疗后观察组前列腺大小和前列腺质量均比治疗前减少,并西药组(P0.01);治疗后观察组夜尿次数少于西药组(P0.01)。结论:桂附地黄丸联合坦洛新治疗BPH(肾阳虚证)患者,能改善下尿路症状,提高患者生活质量,改善了BPH临床进展的高危因素,值得进一步的研究。

Clinical Research of Guifu Dihuang Pills Combined Tamsulosin Hydrochloride Sustained Release Capsules in Treating 60 Patients with Benign Prostatic Hyperplasia

Objective: To observe the effect of Guifu Dihuang pills combined tamsulosin hydrochloride sustained release capsules in treating benign prostatic hyperplasia (BPH) disease of kidney-yang deficiency syndrome. Method: One hundred and sixteen BPH patients were randomly divided into the control group (56 cases) and the observation group (60 cases) via a digital method. Patients in the control group received 0.2 mg tamsulosin hydrochloride sustained release capsules orally once every night. Based on the therapy of the control group, patients in the observation group added 6 g Guifu Dihuang pills orally twice daily. All patients in two groups received 12 weeks of treatment. International prostate symptom scores (I-PSS), kidney-yang deficiency syndrome scores, and quality of life (QOL) scores caused by urination symptom were assessed. Moreover, post-void residual urine volumes (PVR), the maximal urinary flow rates(Q_max) and average urinary flow rates (Q_ave) were measured. Prostate size and quality were tested through type-B ultrasonic. Enuresis nocturia frequencies were recorded. Result: The total curative effect in the observation group was 91.66%, which was superior to 76.78% in the control group (P <0.05). Scores of I-PSS, kidney-YANG deficiency syndrome, QOL in the observation group were less than those in the control group (P <0.01). The PVR in the observation group was lower (P <0.01), the Q_max and Q_ave were higher than those in the control group (P <0.01). After therapy, prostate size and quality decreased as compared with the control group (P <0.01). Frequencies of enuresis nocturia were less than those in the control group (P <0.01). Conclusion: Guifu Dihuang pills combined tamsulosin could ameliorate lower urinery-tract syndrom, improve patients' QOL and ameliorate risk factors of clinical progression in treating BPH patients with kidney-yang syndrome, and it is worthy of further study.